Table 1 Patient characteristics
Factors | Case (younger than 30) | Control (elder counterpart) | Chi square test | PABC 47 cases |
|---|---|---|---|---|
Cases (%) | Cases (%) | P value | Cases (%) | |
Calendar year of surgery | ||||
1986–1995 | 40 (50.0%) | 40 (50.0%) | >0.9999 | 25 (53.2%) |
1996–2002 | 40 (50.0%) | 40 (50.0%) | 22 (46.8%) | |
Age at surgery, years old | ||||
<35 | 80 (100.0%) | 1 (1.3%) | <0.0001 | 20 (42.6%) |
≥35 | 0 (0.0%) | 79 (98.8%) | 27 (57.4%) | |
Family history of breast cancer | ||||
None | 69 (86.3%) | 69 (86.3%) | >0.9999 | 40 (85.1%) |
Positive | 11 (13.8%) | 11 (13.8%) | 7 (14.9%) | |
Years from the last childbirth (YFLC) | ||||
Nulliparous | 68 (85.0%) | 16 (20.0%) | <0.0001 | 4 (8.5%) |
Recent (<8) | 12 (15.0%) | 8 (10.0%) | 43 (91.5%) | |
Past (≥8) | 0 (0.0%) | 56 (70.0%) | 0 (0.0%) | |
Tumor size, cm (Pathological) | ||||
≤2 | 20 (25.0%) | 23 (28.8%) | 0.1826 | 13 (27.7%) |
2.1–5 | 28 (35.0%) | 42 (52.5%) | 21 (44.7%) | |
>5 | 11 (13.8%) | 6 (7.5%) | 5 (10.6%) | |
The number of metastatic lymph nodes | ||||
None | 40 (50.0%) | 38 (47.5%) | 0.3553 | 14 (29.8%) |
1–3 | 24 (30.0%) | 23 (28.8%) | 15 (31.9%) | |
4–9 | 6 (7.5%) | 13 (16.3%) | 11 (23.4%) | |
10– | 9 (11.3%) | 6 (7.5%) | 7 (14.9%) | |
Histological type | ||||
Papillotubular carcinoma | 18 (22.5%) | 24 (30.0%) | 0.1003 | 9 (19.1%) |
Sollid-tubular carcinoma | 28 (35.0%) | 16 (20.0%) | 20 (42.6%) | |
Scirrhous carcinoma | 29 (36.3%) | 27 (33.8%) | 13 (27.7%) | |
Special types | 4 (5.0%) | 10 (12.5%) | 5 (10.6%) | |
Unilateral double cancer | 1 (1.3%) | 3 (3.8%) | 0 (0.0%) | |
Extent of tumor invasion (histological) | ||||
Localized within mammary gland | 29 (36.3%) | 23 (28.8%) | 0.4486 | 22 (46.8%) |
Invading the extramammary fat tissue | 47 (58.8%) | 50 (62.5%) | 21 (44.7%) | |
Invading the skin and/or muscle | 4 (5.0%) | 7 (8.8%) | 4 (8.5%) | |
Lymphovascular invasion | ||||
Absent | 45 (56.3%) | 53(66.3%) | 0.2559 | 24 (51.1%) |
Present | 35 (43.8%) | 27(33.8%) | 23 (48.9%) | |
Estrogen receptor(EIA), fmol/mg | ||||
<5 (negative) | 31 (38.8%) | 30 (37.5%) | 0.2563 | 31 (66.0%) |
5–21 (weakly positive) | 14 (17.5%) | 18 (22.5%) | 2 (4.3%) | |
22– (strongly positive) | 9 (11.3%) | 19 (23.8%) | 4 (8.5%) | |
Not performed | 26 (32.5%) | 13 (16.3%) | 10 (21.3%) | |
Progesterone receptor(EIA), fmol/mg | ||||
<10 (negative) | 23 (28.8%) | 20 (25.0%) | 0.1555 | 23 (48.9%) |
10–95 (Weakly positive) | 15 (18.8%) | 20 (25.0%) | 9 (19.1%) | |
96– (Strongly positive) | 13 (16.3%) | 27 (33.8%) | 3 (6.4%) | |
Not performed | 29 (36.3%) | 13 (16.3%) | 12 (25.5%) | |
Type of breast surgery | ||||
Breast conserving surgery (BCS) | 27 (33.8%) | 16 (20.0%) | 0.0738 | 6 (12.8%) |
Mastectomy | 53 (66.3%) | 64 (80.0%) | 41 (87.2%) | |
Chemotherapy | ||||
None | 24 (30.0%) | 28 (35.0%) | 0.3417 | 12 (25.5%) |
Others | 5 (6.3%) | 10 (12.5%) | 8 (17.0%) | |
CMF | 33 (41.3%) | 31 (38.8%) | 14 (29.8%) | |
Anthracycline | 13 (16.3%) | 8 (10.0%) | 8 (17.0%) | |
Anthracycline and Taxane | 5 (6.3%) | 2 (2.5%) | 5 (10.6%) | |
Hormone therapy | ||||
Ovarian function suppression ± others | 11 (13.8%) | 7 (8.8%) | 0.0007 | 4 (8.5%) |
Selective estrogen receptor modulators | 8 (10.0%) | 28 (35.0%) | 10 (21.3%) | |
Others, none | 61 (76.3%) | 45 (56.3%) | 33 (70.2%) | |
Radiation therapy (RT) | ||||
Not performed | 63 (78.8%) | 68 (85.0%) | 0.3149 | 42 (89.4%) |
Performed | 17 (21.3%) | 12 (15.0%) | 5 (10.6%) | |